Bu-Shu Xu
Impact in
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Inflammatory Biomarkers in Disease Prognosis
Papers in
- Oncology 14
- CAR-T cell therapy research 5
- Vascular Tumors and Angiosarcomas 4
- Inflammatory Biomarkers in Disease Prognosis 2
- Cancer Immunotherapy and Biomarkers 2
-
- Sarcoma Diagnosis and Treatment 8
- Co-authors
- Xing Zhang (17 shared papers)Yi Que (10 shared papers)Mengmeng Liu (1 shared paper)Jing Yang (1 shared paper)Qiuzhong Pan (11 shared papers)Wei Xiao (5 shared papers)Yao Liang (5 shared papers)Zhiwei Zhou (2 shared papers)
In The Last Decade
Bu-Shu Xu
20 papers receiving 416 citations
Peers
Comparison fields: 5 of 53
- Oncology 190
- Otorhinolaryngology 18
- Immunology 72
- Pulmonary and Respiratory Medicine 99
- Cancer Research 39
Countries citing papers authored by Bu-Shu Xu
This map shows the geographic impact of Bu-Shu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bu-Shu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bu-Shu Xu more than expected).
Fields of papers citing papers by Bu-Shu Xu
This network shows the impact of papers produced by Bu-Shu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bu-Shu Xu. The network helps show where Bu-Shu Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Bu-Shu Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 84 | |
| 2 | 2021 | 77 | |
| 3 | 2021 | 70 | |
| 4 | 2013 | 49 | |
| 5 | 2023 | 21 | |
| 6 | 2024 | 19 | |
| 7 | 2020 | 18 | |
| 8 | 2019 | 16 | |
| 9 | 2022 | 16 | |
| 10 | 2021 | 14 | |
| 11 | 2023 | 8 | |
| 12 | 2019 | 8 | |
| 13 | 2021 | 5 | |
| 14 | 2024 | 3 | |
| 15 | 2022 | 3 | |
| 16 | 2023 | 2 | |
| 17 | 2023 | 1 | |
| 18 | 2024 | 1 | |
| 19 | 2025 | 1 | |
| 20 | 2016 | 1 |
About Bu-Shu Xu
Bu-Shu Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Biotechnology and Pathology and Forensic Medicine, having authored 22 papers that have together received 417 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (5 papers), Vascular Tumors and Angiosarcomas (4 papers), Cancer Research and Treatments (3 papers), Inflammatory Biomarkers in Disease Prognosis (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Oncology (190 citations), Otorhinolaryngology (18 citations), Immunology (72 citations), Pulmonary and Respiratory Medicine (99 citations) and Cancer Research (39 citations). Bu-Shu Xu has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Xing Zhang, Yi Que, Mengmeng Liu, Jing Yang, Qiuzhong Pan, Wei Xiao, Yao Liang, Zhiwei Zhou, Desheng Weng and Shu-Mei Yan. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cancer, Clinical Cancer Research, Advanced Science and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.